Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.

Liang, Jin-Yan; Tong, Fan; Gu, Fei-Fei; Liu, Yang-Yang; Zeng, Yu-Lan; Hong, Xiao-Hua; Zhang, Kai; Liu, Li

Liang, Jin-Yan; Tong, Fan; Gu, Fei-Fei; Liu, Yang-Yang; Zeng, Yu-Lan; Hong, Xiao-Hua; Zhang, Kai; Liu, Li.

Affiliation

Liang JY; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Medicine (Baltimore) ; 96(21): e6985, 2017 May.

Article in En | MEDLINE | ID: mdl-28538405

Subject(s)

Adenocarcinoma/drug therapy; Albumins/therapeutic use; Antineoplastic Agents/therapeutic use; Carcinoma, Neuroendocrine/drug therapy; ErbB Receptors/genetics; Lung Neoplasms/drug therapy; Paclitaxel/therapeutic use; Adenocarcinoma/genetics; Adenocarcinoma/pathology; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine/genetics; Carcinoma, Neuroendocrine/pathology; Erlotinib Hydrochloride/therapeutic use; Fatal Outcome; Humans; Liver Neoplasms/drug therapy; Liver Neoplasms/secondary; Lung Neoplasms/genetics; Lung Neoplasms/pathology; Male; Middle Aged; Mutation

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Paclitaxel / Carcinoma, Neuroendocrine / Albumins / ErbB Receptors / Lung Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans / Male / Middle aged Language: En Journal: Medicine (Baltimore) Year: 2017 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google